Cholangiocarcinoma risk factors and the potential role of aspirin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Landscape of mFrontiers in pharmacology · 2024
   Review
2. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies.Seminars in interventional radiology · 2021
   Review
3. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.World journal of gastrointestinal oncology · 2021
   Review
4. Long Noncoding RNA GAS5 Accelerates Cholangiocarcinoma Progression by Regulating hsa-miR-1297.Cancer management and research · 2021
   Article
5. Identification of candidate genes for the diagnosis and treatment of cholangiocarcinoma using a bioinformatics approach.Oncology letters · 2019
   Article
6. Molecular Pathogenesis of Cholangiocarcinoma.BMC cancer · 2019
   Review

Corrections and comments

• Comment on
  Aspirin use and the risk of cholangiocarcinoma.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as